Further, the sensitivity of certain molecularly or genetically defined AML subgroups (defined by MN1 expression or NPM1 mutations, respectively) was not confirmed in subsequent studies [20,27,29,30,31,32]. This evidence concerns the gene NPM1 and acute myeloid leukemia.